论文部分内容阅读
目的观察口服益生菌即双歧、嗜酸乳杆菌,肠球菌三联活菌胶囊对缓解期溃疡性结肠炎(UC)的维持缓解作用,比较美沙拉秦与双歧、嗜酸乳杆菌,肠球菌三联活菌胶囊对维持缓解期UC的疗效。方法采用随机对照方法观察78例活动期UC经治疗后处于缓解期的患者,给予美沙拉秦钠或口服双歧、嗜酸乳杆菌,肠球菌三联活菌胶囊,疗程为1a。结果治疗1年末,口服双歧、嗜酸乳杆菌,肠球菌三联活菌胶囊组维持缓解率为69.44%,复发率为30.56%;美沙拉秦组维持缓解率为72.22%,复发率为27.78%;2组复发率相比,差异无统计学意义(P>0.05)。结论口服双歧、嗜酸乳杆菌,肠球菌三联活菌胶囊对缓解期UC维持缓解有较好的疗效,与美沙拉秦的疗效相近。
Objective To observe the effects of oral probiotics, such as bifidobacterium, Lactobacillus acidophilus and enterococci, on the maintenance and remission of ulcerative colitis (UC) in remission stage. To compare the effects of mesalamine and bifidobacteria, Lactobacillus acidophilus, Trials of viable capsule to maintain the efficacy of remission UC. Methods A randomized controlled clinical trial was conducted in 78 patients with active stage UC who were in remission after treatment. Mesalazine sodium or oral bifidobacterium, Lactobacillus acidophilus and enterococci were used in the study. The course of treatment was 1a. Results At the end of 1 year of treatment, the oral remission rate of Bifidobacterium, Lactobacillus acidophilus and enterococci was 69.44% and the recurrence rate was 30.56%. The remission rate of mesalamine group was 72.22% and the recurrence rate was 27.78% There was no significant difference in relapse rate between the two groups (P> 0.05). Conclusion oral bifidobacterium, Lactobacillus acidophilus, enterococci triple viable capsule on remission of UC to maintain a good response, with similar efficacy of mesalazine.